

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



21st October, 2015.

Mrs. S. Subramanian. DCS-CRD
The Secretary
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

The Manager,
Listing Department,
National Stock Exchange of India Ltd,
"Exchange Plaza", C-1, Block - G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.

Ref: Compliance of Clause 41 of the Listing Agreement

Script Code: 532637

Symbol: MANGALAM

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter and half year ended 30th September, 2015.

In terms of Clause 41 of the Listing Agreement(s), we are forwarding herewith Unaudited Financial Results for the quarter and half year ended 30th September, 2015 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 21st October, 2015 at Mumbai along with Limited Review Report of the said period.


Further please note that the Company has made necessary arrangement to publish the same in the newspaper as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.


(GOVARDHAN M. DHOOT)
DIRECTOR
Din No.01240086



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>


Un- Audited Financial Results(Provisional) for the Quarter and Half Year ended 30th September 2015 approved and taken on record by the Board at their meeting dated 21st October 2015

Sr. No.	Particulars	Unaudited			Unaudited		(Rs. in Lacs)
		Quarter ended			Half year ended		Audited
		3 months ended	3 months ended	Corresponding 3 months ended in the previous period	Year to date figures for Current period ended	Year to date figures for the previous period ended	Year Ended
		30.09.15	30.06.15	30.09.14	30.09.15	30.09.14	31.03.15
A PART I - STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2015							
1	Sales/Income from operation(Net of Excise duty)	7255.60	6956.09	4084.93	14211.69	7940.74	22058.39
2	Other Operating Income	0.00	2.72	264.97	2.72	272.71	7.47
3	Total Net Income from Operation	7255.60	6958.81	4349.90	14214.41	8213.45	22065.86
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	(1075.92)	751.76	1050.87	(324.16)	898.71	(745.54)
	(b) Consumption of raw materials	5930.01	4376.72	1698.64	10306.73	4464.35	16324.04
	(c) Employee Benefits	359.17	304.75	275.09	663.92	528.27	1095.20
	(d) Depreciation	109.45	108.25	93.63	217.70	200.53	415.40
	(e) Other expenditure	1241.70	880.23	745.16	2121.93	1386.22	3352.68
	(f) Total	6564.41	6421.71	3863.39	12986.12	7478.08	20441.78
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	691.19	537.10	486.51	1228.29	735.37	1624.08
6	Other income	2.37	70.55	2.69	72.92	4.88	5.17
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	693.56	607.65	489.20	1301.21	740.25	1629.25
8	Finance Cost	223.64	232.39	273.64	456.03	544.99	1028.37
9	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	469.92	375.26	215.56	845.18	195.26	600.88
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	469.92	375.26	215.56	845.18	195.26	600.88
12	Tax Expenses(incl Deferred Tax)	105.00	70.00	15.00	175.00	15.00	(13.24)
13	Net Profit(+)/Loss(-) after Tax (11-12)	364.92	305.26	200.56	670.18	180.26	614.12
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	364.92	305.26	200.56	670.18	180.26	614.12
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	1317.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1618.59
18	Earning per share (EPS)						
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.77	2.32	1.52	5.09	1.37	4.66
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.77	2.32	1.52	5.09	1.37	4.66
A PART II - PARTICULARS OF SHAREHOLDING							
1	Non Promoters Shareholding						
	- Number of shares	7619615	7619615	7628115	7619615	7628115	7628115
	- Percentage of shareholding	57.82	57.82	57.88	57.82	57.88	57.88
2	Promoters and Promoter group Shareholding						
	a) Pledged/ Encumbered						
	Number of Shares	4050133	4050133	5491228	4050133	5491228	4050133
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	72.86	72.86	98.94	72.86	98.94	72.97
	Percentage of Shares (as a % of the total share capital of the company)	30.73	30.73	41.67	30.73	41.67	30.73
	b) Non-encumbered						
	Number of Shares	1508500	1508500	58905	1508500	58905	1500000
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	27.14	27.14	1.06	27.14	1.06	27.03
	Percentage of Shares (as a % of the total share capital of the company)	11.45	11.45	0.45	11.45	0.45	11.39
B INVESTOR COMPLAINTS		3 Months ended 30.09.15					
	Pending at the Beginning of the Quarter			Nil			
	Received during the Quarter			Nil			
	Disposed of during the Quarter			Nil			
	Remaining unresolved at the end of the Quarter			Nil			

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 21st October 2015.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- Depreciation has been calculated as per new amended Rules of the Company's Act 2013 and the resultant difference in gross depreciation at the beginning of the year of Rs. 15,54,124/- has been adjusted in the retained earnings under the Head Reserves & Surplus for the Half Year Ended 30th September 2015.
- Previous year figure are regrouped where ever necessary.

MILWANI ASSOCIATES
Chartered Accountants
F.R.N.:106405W
31/33, Dr. M. B. Velkar St.,
Mumbai - 400 009
Membership No.: 36099
F.R.N.:106405W

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri. Govardhan M. Dhoot)
Chairman

MANGALAM DRUGS & ORGANICS LTD.

Statement Of Assets & Liabilities (Un-Audited) As at 30th Sept 2015, Required Under Clause 41 Of Listing Agreement

(Rs. In Lacs)

S.No.	Particulars	Half Year ended (Un-audited) 30.09.2015	Year Ended (Audited) 31.03.2015
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,317.82	1,317.82
	(b) Reserves and surplus	2,273.31	1,618.59
	(c) Money recd against Share Warrants	1,550.25	-
	Sub Total -Shareholders Funds	5,141.38	2,936.41
2	Non-current liabilities		
	(a) Long-term borrowings	2,355.40	3,937.04
	(b) Deferred Tax Liabilities (Net)	344.80	169.80
	Sub Total -Non-Current Liabilities	2,700.20	4,106.84
3	Current liabilities		
	(a) Short-term borrowings	3,462.14	3,182.43
	(b) Trade payables	3,367.17	5,477.29
	(c) Other current liabilities	1,128.55	1,286.53
	Sub Total -Current Liabilities	7,957.86	9,946.25
	TOTAL	15,799.44	16,989.50
B	ASSETS		
1	I) Non-current assets		
	(a) Fixed Assets	5252.56	5294.79
	(b) Long-term loans and advances	98.55	91.02
	Sub Total -Non-Current Assets	5,351.11	5,385.81
2	Current assets		
	(a) Current Investments	24.02	24.02
	(b) Inventories	6,449.75	5,734.04
	(c) Trade receivables	2,361.78	4,424.69
	(d) Cash and cash equivalents	57.29	67.94
	(e) Short-term loans and advances	1,555.49	1,353.00
	Sub Total -Current Assets	10,448.33	11,603.69
	TOTAL	15,799.44	16,989.50

Notes: 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: 21.10.2015On behalf of Board of Directors
For Mangalam Drugs & Organics LtdChairman
(Shri Govardhan M. Dhoot)



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.

Tel.: 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

LIMITED REVIEW REPORT


We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at Rupam Building, 3rd Floor, 239 P.D'Mello Road, Near GPO, Mumbai - 400001; for the quarter and half year ended 30th Sept'2015 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai

Date : 21st October 2015.


(RAKESH K. MILWANI)
PROPRIETOR, MILWANI ASSOCIATES
Membership No. 36099
Firm Registration No.: 106405W